American Diabetes Association (ADA) 2026 Medical Meeting

Research evidence excerpt

American Diabetes Association (ADA) 2026 Medical Meeting

17% and pediatric T2 DKA risk

also rose over the same period. (4) nearly half of DKA hospitalizations are not recognized as DKA

on admission; notably, 45% of DKA hospitalizations were give a non-DKA diagnosis and most

of those were nonspecific or GI-related symptoms easily mistaken for stomach flu; (5) The true

burden is underestimated as secondary-position DKA diagnosis in T2D rose faster than primary

diagnosis, meaning analyses focused on primary DKA underrate the problem. (6) acuity remains

high with 96% of DKA episodes requiring inpatient admissions; (7) CGM alone isn’t enough as

DKA events still occur after CGM initiation, signaling the need for an additional prevention layer.

Overall, ABT believes ketone monitoring is the missing piece and while adults with T1D recognize

its importance, the real-world use is infrequent and reactive, not proactive.; and (8) ~10% of DKA

events occur without elevated blood glucose levels. Overall, our KOL expects usage in 20-25%

of pediatric market and 10% of adult market initially with the potential for market expansion

depending on pricing and reimbursement.

ABT: Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for

people with diabetes (5/27; see full press release here). This is a first-of-its-kind biowearables

combine continuous glucose and ketone monitoring in a single sensor to support both daily

diabetes management and help detect rising ketone levels that can lead to diabetic ketoacidosis,

a serious health condition for people with diabetes. It integrates with the Libre digital health

ecosystem, allowing people to share glucose and ketone data with caregivers and healthcare

providers.